Responsive image

Drug Information

Drug Generic Name OMALIZUMAB
Drug Class ALLERGEN IMMUNOTHERAPY
Chapter Respiratory System

Indications: prophylaxis of allergic asthma Cautions: autoimmune disease; susceptibility to helminth infection (discontinue if infection does not respond to anthelmintic).

Hepatic impairment manufacturer advises caution—no information available.

Renal impairment manufacturer advises caution (no information available).

Pregnancy manufacturer advises avoid unless essential Breast-feeding manufacturer advises avoid (present in milk in animal studies).

Side-effects : abdominal pain, headache, pyrexia. less commonly dyspepsia, nausea, diarrhoea, weight gain, postural hypotension, flushing, pharyngitis, bronchospasm, cough, syncope, paraesthesia, dizziness, drowsiness, malaise, influenza-like illness,photosensitivity, urticaria, rash, pruritus; rarely laryngoedema, parasitic infection, antibody formation; also reported arterial thromboembolic events, Churg- Strauss syndrome, thrombocytopenia, arthralgia, myalgia, joint swelling, alopecia, serum sickness (including fever and lymphadenopathy)

Dose: By subcutaneous injection, ADULT and CHILD over 6 years, according to immunoglobulin E concentration and body-weight.

Brand Name
  • Xolair Injection, 150 mg/ml, 0.5-ml (75-mg) prefilled syringe 1-ml (150-mg) prefilled syringe
rating - 1 starrating - 2 starrating - 3 starrating - 4 starrating - 5 star